A phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer

Cristian Lolli, Valentina Gallà, Giuseppe Schepisi, Domenico Barone, Salvatore Luca Burgio, Antonio Maugeri, Bernadette Vertogen, Dino Amadori, Ugo de Giorgi

Research output: Contribution to journalArticle

Abstract

Background. Everolimus is standard of care in the treatment of patients affected by metastatic renal cell carcinoma (mRCC) that has progressed after at least one previous line of treatment. Stomatitis and noninfectious pneumonitis (NIP) are common adverse events (AEs) in patients treated with everolimus. Prednisone could reduce the incidence of stomatitis, and it is commonly used to treat NIP. We hypothesized that low doses of prednisone could reduce the incidence and/or the severity of everolimus-induced NIP and stomatitis. Methods.We have conducted an open-label, single-arm, phase II trial of prednisone 5 mg b.i.d. added to everolimus 10 mg/ day in patients with mRCC.We planned to evaluate the safety, tolerability, and activity of this combination in mRCC patients. We aimed to reduce incidence of drug discontinuations due to stomatitis or NIP from25% to 10%. Results. Three (38%) of the first eight patients enrolled experienced grade ≥2 pneumonitis and stopped treatment. Grade 1 stomatitis occurred in only one patient (13%). Five of eight patients experienced disease progression at the 2-month evaluation. Two patients (25%) were reported free of disease progression at 1 year of treatment. Conclusion. The incidence of NIP in these patients was considered too high for completing accrual of this study. These results may be of interest for investigating the pathogenesis of NIP and suggest that patients should be carefully followed if treated with chronic corticosteroids while receiving everolimus.

Original languageEnglish
JournalOncologist
Volume22
Issue number7
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Prednisone
Renal Cell Carcinoma
Stomatitis
Pneumonia
Incidence
Disease Progression
Everolimus
Therapeutics
Standard of Care
Adrenal Cortex Hormones
Safety

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer. / Lolli, Cristian; Gallà, Valentina; Schepisi, Giuseppe; Barone, Domenico; Burgio, Salvatore Luca; Maugeri, Antonio; Vertogen, Bernadette; Amadori, Dino; de Giorgi, Ugo.

In: Oncologist, Vol. 22, No. 7, 01.07.2017.

Research output: Contribution to journalArticle

@article{c6561e11de1b45df9dad2c63eafdee91,
title = "A phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer",
abstract = "Background. Everolimus is standard of care in the treatment of patients affected by metastatic renal cell carcinoma (mRCC) that has progressed after at least one previous line of treatment. Stomatitis and noninfectious pneumonitis (NIP) are common adverse events (AEs) in patients treated with everolimus. Prednisone could reduce the incidence of stomatitis, and it is commonly used to treat NIP. We hypothesized that low doses of prednisone could reduce the incidence and/or the severity of everolimus-induced NIP and stomatitis. Methods.We have conducted an open-label, single-arm, phase II trial of prednisone 5 mg b.i.d. added to everolimus 10 mg/ day in patients with mRCC.We planned to evaluate the safety, tolerability, and activity of this combination in mRCC patients. We aimed to reduce incidence of drug discontinuations due to stomatitis or NIP from25{\%} to 10{\%}. Results. Three (38{\%}) of the first eight patients enrolled experienced grade ≥2 pneumonitis and stopped treatment. Grade 1 stomatitis occurred in only one patient (13{\%}). Five of eight patients experienced disease progression at the 2-month evaluation. Two patients (25{\%}) were reported free of disease progression at 1 year of treatment. Conclusion. The incidence of NIP in these patients was considered too high for completing accrual of this study. These results may be of interest for investigating the pathogenesis of NIP and suggest that patients should be carefully followed if treated with chronic corticosteroids while receiving everolimus.",
author = "Cristian Lolli and Valentina Gall{\`a} and Giuseppe Schepisi and Domenico Barone and Burgio, {Salvatore Luca} and Antonio Maugeri and Bernadette Vertogen and Dino Amadori and {de Giorgi}, Ugo",
year = "2017",
month = "7",
day = "1",
doi = "10.1634/theoncologist.2017-0154",
language = "English",
volume = "22",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",
number = "7",

}

TY - JOUR

T1 - A phase II study of everolimus plus oral prednisone in patients with metastatic renal cell cancer

AU - Lolli, Cristian

AU - Gallà, Valentina

AU - Schepisi, Giuseppe

AU - Barone, Domenico

AU - Burgio, Salvatore Luca

AU - Maugeri, Antonio

AU - Vertogen, Bernadette

AU - Amadori, Dino

AU - de Giorgi, Ugo

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Background. Everolimus is standard of care in the treatment of patients affected by metastatic renal cell carcinoma (mRCC) that has progressed after at least one previous line of treatment. Stomatitis and noninfectious pneumonitis (NIP) are common adverse events (AEs) in patients treated with everolimus. Prednisone could reduce the incidence of stomatitis, and it is commonly used to treat NIP. We hypothesized that low doses of prednisone could reduce the incidence and/or the severity of everolimus-induced NIP and stomatitis. Methods.We have conducted an open-label, single-arm, phase II trial of prednisone 5 mg b.i.d. added to everolimus 10 mg/ day in patients with mRCC.We planned to evaluate the safety, tolerability, and activity of this combination in mRCC patients. We aimed to reduce incidence of drug discontinuations due to stomatitis or NIP from25% to 10%. Results. Three (38%) of the first eight patients enrolled experienced grade ≥2 pneumonitis and stopped treatment. Grade 1 stomatitis occurred in only one patient (13%). Five of eight patients experienced disease progression at the 2-month evaluation. Two patients (25%) were reported free of disease progression at 1 year of treatment. Conclusion. The incidence of NIP in these patients was considered too high for completing accrual of this study. These results may be of interest for investigating the pathogenesis of NIP and suggest that patients should be carefully followed if treated with chronic corticosteroids while receiving everolimus.

AB - Background. Everolimus is standard of care in the treatment of patients affected by metastatic renal cell carcinoma (mRCC) that has progressed after at least one previous line of treatment. Stomatitis and noninfectious pneumonitis (NIP) are common adverse events (AEs) in patients treated with everolimus. Prednisone could reduce the incidence of stomatitis, and it is commonly used to treat NIP. We hypothesized that low doses of prednisone could reduce the incidence and/or the severity of everolimus-induced NIP and stomatitis. Methods.We have conducted an open-label, single-arm, phase II trial of prednisone 5 mg b.i.d. added to everolimus 10 mg/ day in patients with mRCC.We planned to evaluate the safety, tolerability, and activity of this combination in mRCC patients. We aimed to reduce incidence of drug discontinuations due to stomatitis or NIP from25% to 10%. Results. Three (38%) of the first eight patients enrolled experienced grade ≥2 pneumonitis and stopped treatment. Grade 1 stomatitis occurred in only one patient (13%). Five of eight patients experienced disease progression at the 2-month evaluation. Two patients (25%) were reported free of disease progression at 1 year of treatment. Conclusion. The incidence of NIP in these patients was considered too high for completing accrual of this study. These results may be of interest for investigating the pathogenesis of NIP and suggest that patients should be carefully followed if treated with chronic corticosteroids while receiving everolimus.

UR - http://www.scopus.com/inward/record.url?scp=85024111426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024111426&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2017-0154

DO - 10.1634/theoncologist.2017-0154

M3 - Article

AN - SCOPUS:85024111426

VL - 22

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 7

ER -